{"id":"NCT05815758","sponsor":"Bausch & Lomb Incorporated","briefTitle":"Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution","officialTitle":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-04-20","primaryCompletion":"2023-09-18","completion":"2023-09-18","firstPosted":"2023-04-18","resultsPosted":"2025-07-10","lastUpdate":"2025-07-10"},"enrollment":512,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Allergic Conjunctivitis"],"interventions":[{"type":"DRUG","name":"Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo)","otherNames":[]},{"type":"DRUG","name":"Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution","otherNames":[]}],"arms":[{"label":"Brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution","type":"EXPERIMENTAL"},{"label":"Vehicle ophthalmic solution","type":"ACTIVE_COMPARATOR"}],"summary":"To compare the safety and tolerability of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% combination ophthalmic solution versus its vehicle in healthy adult subjects and in pediatric subjects.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Baseline up to Day 42","effectByArm":[{"arm":"Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution","deltaMin":61,"sd":null},{"arm":"Vehicle Ophthalmic Solution","deltaMin":19,"sd":null}],"pValues":[]},"eligibility":{"minAge":"5 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":2},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":340},"commonTop":["Eye disorders","General disorders and administration site conditions","Instillation site irritation","Conjunctival Hyperaemia"]}}